Observational study on the prognosis of pulmonary artery sarcoma
A Multicenter, Observational Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.
This study follows patients with pulmonary artery sarcoma for three years to see how they are doing and understand their survival outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Sex | All |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06165718 on ClinicalTrials.gov |
What this trial studies
This observational study follows patients diagnosed with pulmonary artery sarcoma over a period of at least 36 months to investigate their survival outcomes. The study is conducted across various locations in mainland China, including major hospitals. It aims to gather data on the clinical roadmap and prognosis of this rare condition, providing insights into patient outcomes and disease progression.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with pulmonary artery sarcoma who can provide informed consent and have intraluminal defects indicated by imaging.
Not a fit: Patients with a life expectancy of less than 3 months due to other diseases or those unable to complete follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of pulmonary artery sarcoma prognosis and improve patient management strategies.
How similar studies have performed: While there may be limited studies specifically on pulmonary artery sarcoma, observational studies in similar rare cancers have shown success in understanding prognosis and improving patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Computed tomography pulmonary angiography indicated that there were intraluminal defects * Malignant histopathology was sarcoma * Informed consent form was signed Exclusion Criteria: * Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma * Expected inability to complete follow-up
Where this trial is running
Beijing, Beijing
- China-Japan Friendship Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Wanmu Xie — China-Japan Friendship Hospital
- Study coordinator: Wanmu Xie
- Email: xiewanmu@126.com
- Phone: +86 15611734410
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.